Generated June 8, 2026 at 8:31 PM ET
· Covers June 8 trading day
· 10 of 225 ready 8-Ks selected
· AI-assisted overview
The day's highest-materiality filings included bankruptcies at GoHealth (Chapter 11) and Inotiv (Chapter 11 with delisting), plus a merger announcement between Standard BioTools and Treeline Biosciences. Perrigo's CEO resigned after a conduct violation, while Incyte agreed to acquire Vega Therapeutics for up to $2.0B. Several companies addressed Nasdaq compliance: aTyr Pharma received an extension, Teads regained compliance, and Vivos Therapeutics received a bid price deficiency notice. Kartoon Studios reported a $28.5M settlement, and Quantum Space announced a SPAC merger with Inflection Point Acquisition Corp.
leadership
negative
materiality 0.80
June 8, 2026, 4:22 PM ET
Perrigo CEO resigns after conduct violation; Board appoints Albert Manzone as interim CEO
- Patrick Lockwood-Taylor resigned as President, CEO, and Board member effective June 7, 2026, after Board found personal conduct violated Code of Conduct.
- Albert A. Manzone, Board member since 2022, appointed Interim President and CEO; comprehensive search for permanent CEO initiated.
- Resignation unrelated to Perrigo's business, strategy, operations, financial reporting, or results.
VVOS
Vivos Therapeutics, Inc.
regulatory
negative
materiality 0.80
June 8, 2026, 8:30 AM ET
Vivos Therapeutics enters debt-to-equity exchange; receives Nasdaq bid price deficiency notice
- Exchange agreement to convert up to $4.5M of Streeterville debt into non-convertible preferred and common stock, contingent on equity financings of at least $2.6M (first tranche) by June 15, 2026.
- Streeterville suspends monthly principal redemptions until Sept 15, 2026; reduces monthly cap to $225K; extends note maturity to June 10, 2027.
- Vivos issued V-Co Investors 4 LLC a $5M convertible note (initial $500K draw) to support proposed $5.5M equity financing expected by June 30, 2026.
M&A
positive
materiality 0.80
June 8, 2026, 7:05 AM ET
Incyte to acquire Vega Therapeutics for $1.25B upfront; total up to $2.0B
- Acquires Vega Therapeutics from Star Therapeutics; adds VGA039, a Phase 3 anti-Protein S mAb for von Willebrand disease.
- Star receives $1.25B upfront; up to $750M in sales milestones for total consideration of $2.0B.
- VGA039 has Breakthrough Therapy, Fast Track, and orphan drug designations from FDA; Phase 3 VIVID-6 trial ongoing.
debt
negative
materiality 0.95
June 8, 2026, 6:06 AM ET
GoHealth files for Chapter 11 bankruptcy with prepackaged plan supported by 100% of lenders
- GoHealth filed Chapter 11 on June 7, 2026; 100% of lenders, >60% of Class A common holders, and >99% of GoHealth Holdings unitholders support the prepackaged plan.
- CEO Vijay Kotte received $2.87 million cash award under the 2026 Cash Performance Plan upon the Chapter 11 filing.
- COO Michael Hargis departed June 5, 2026; treated as termination without cause entitling him to severance.
LAB
STANDARD BIOTOOLS INC.
M&A
neutral
materiality 1.00
June 8, 2026, 8:31 AM ET
Standard BioTools to merge with Treeline Biosciences in all-stock deal; LAB stockholders to own ~16%
- All-stock merger; Treeline valued at $2.5B, Standard BioTools at ~$460M; combined co. to be named Treeline Biosciences Holdings.
- Former LAB stockholders to hold ~16% of combined co., Treeline stockholders ~84%; closing expected H2 2026.
- Legacy mass cytometry/microfluidics business to be sold or wound down; CVRs issued to LAB stockholders for proceeds.
TOON
Kartoon Studios, Inc.
litigation
positive
materiality 0.75
June 8, 2026, 4:09 PM ET
Kartoon Studios receives $28.475M aggregate settlement from lawsuit defendants
- Settlement in Augenbaum v. Anson Investments Master Fund LP et al., S.D.N.Y. Case No. 1:22-CV-00249-AS.
- Five settling parties pay $28,475,000 aggregate, less plaintiff counsel fees/expenses, with mutual releases.
- Court approved three settlements on June 2 and June 4, 2026; two remaining pending court approval.
IPFX
Inflection Point Acquisition Corp. VI
M&A
positive
materiality 0.85
June 8, 2026, 7:17 AM ET
Quantum Space to go public via SPAC merger with Inflection Point at ~$1.2B post-money equity
- Pre-money equity value of $600M; post-combination equity value ~$1.2B assuming no redemptions.
- $300M PIPE at $12/share anchored by Inflection Point Asset Management; trust adds ~$253M.
- Quantum Space has 6 contracts/proposals with U.S. Space Force, DoD, DARPA; eligible for $6.2B Andromeda IDIQ.
regulatory
negative
materiality 0.60
June 8, 2026, 4:04 PM ET
aTyr Pharma receives Nasdaq extension to Nov 30, 2026 to cure bid price deficiency
- Original bid price deficiency notice received Dec 4, 2025; stock closed below $1.00 for 30 consecutive days.
- On June 3, 2026, Nasdaq granted additional 180-day compliance period until November 30, 2026.
- Company must maintain closing bid price >= $1.00 for 10 consecutive business days to regain compliance.
regulatory
positive
materiality 0.60
June 8, 2026, 4:16 PM ET
Teads regains Nasdaq minimum bid price compliance; delisting risk removed
- Nasdaq confirmed closing bid price at or above $1.00 for 10 consecutive business days (May 18–June 4, 2026).
- Company had been non-compliant since December 22, 2025; compliance deadline was June 22, 2026.
- Common stock (TEAD) continues trading on Nasdaq Global Select Market; matter is closed.
other material
negative
materiality 1.00
June 8, 2026, 5:02 PM ET
Inotiv enters $65.5M DIP financing, Nasdaq to delist shares June 11; expects total equity loss
- DIP facility: $25M new money term loans + $40.5M roll-up of prepetition bridge loans; interest at Adjusted Term SOFR + 11.5%.
- Nasdaq notified Inotiv of delisting due to Chapter 11 filing; trading suspended June 11, 2026.
- Company states Plan contemplates cancellation of all existing equity interests with no distribution – total loss for shareholders.